Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
暂无分享，去创建一个
G. Linette | P. Ascierto | Xia Li | A. Ribas | W. Miller | M. Postow | P. Nathan | C. Robert | T. Kuzel | D. Lawrence | M. Butler | J. Lutzky | A. Algazi | M. Gordon | B. Curti | P. Robbins | J. A. Blake-Haskins